Metropolitan Life Insurance Company (MetLife)’s Progenics Pharmaceuticals Inc PGNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-30,577
| Closed | -$116K | – | 2631 |
|
|
2020
Q1 | $116K | Buy |
30,577
+874
| +3% | +$3.77K | ﹤0.01% | 1941 |
|
|
2019
Q4 | $151K | Buy |
29,703
+9,429
| +47% | +$49.9K | ﹤0.01% | 2095 |
|
|
2019
Q3 | $102K | Sell |
20,274
-4,938
| -20% | -$24.6K | ﹤0.01% | 2290 |
|
|
2019
Q2 | $156K | Buy |
25,212
+4,460
| +21% | +$21.5K | ﹤0.01% | 2056 |
|
|
2019
Q1 | $96.3K | Sell |
20,752
-6,769
| -25% | -$30.6K | ﹤0.01% | 2345 |
|
|
2018
Q4 | $116K | Buy |
27,521
+3,538
| +15% | +$18K | ﹤0.01% | 2174 |
|
|
2018
Q3 | $150K | Hold |
23,983
| – | – | ﹤0.01% | 2199 |
|
|
2018
Q2 | $193K | Hold |
23,983
| – | – | ﹤0.01% | 1966 |
|
|
2018
Q1 | $179K | Buy |
23,983
+7,075
| +42% | +$47K | ﹤0.01% | 1957 |
|
|
2017
Q4 | $101K | Buy |
+16,908
| New | +$103K | ﹤0.01% | 2307 |
|
|
2017
Q3 | – | Sell |
-48,263
| Closed | -$328K | – | 2560 |
|
|
2017
Q2 | $328K | Hold |
48,263
| – | – | ﹤0.01% | 2000 |
|
|
2017
Q1 | $456K | Buy |
48,263
+2,291
| +5% | +$22.9K | ﹤0.01% | 1708 |
|
|
2016
Q4 | $397K | Sell |
45,972
-3,102
| -6% | -$22.9K | ﹤0.01% | 1881 |
|
|
2016
Q3 | $311K | Sell |
49,074
-1,113
| -2% | -$6.73K | ﹤0.01% | 2044 |
|
|
2016
Q2 | $212K | Hold |
50,187
| – | – | ﹤0.01% | 2286 |
|
|
2016
Q1 | $219K | Hold |
50,187
| – | – | ﹤0.01% | 2117 |
|
|
2015
Q4 | $308K | Buy |
50,187
+4,820
| +11% | +$31.6K | ﹤0.01% | 1945 |
|
|
2015
Q3 | $259K | Sell |
45,367
-3,837
| -8% | -$29.4K | ﹤0.01% | 2101 |
|
|
2015
Q2 | $367K | Buy |
+49,204
| New | +$298K | ﹤0.01% | 1966 |
|
|
2015
Q1 | – | Sell |
-53,538
| Closed | -$405K | – | 2527 |
|
|
2014
Q4 | $405K | Hold |
53,538
| – | – | ﹤0.01% | 1917 |
|
|
2014
Q3 | $278K | Sell |
53,538
-17,190
| -24% | -$85.7K | ﹤0.01% | 2137 |
|
|
2014
Q2 | $305K | Hold |
70,728
| – | – | ﹤0.01% | 2192 |
|
|
2014
Q1 | $289K | Buy |
70,728
+6,309
| +10% | +$32.3K | ﹤0.01% | 2208 |
|
|
2013
Q4 | $343K | Buy |
64,419
+23,250
| +56% | +$102K | ﹤0.01% | 2083 |
|
|
2013
Q3 | $207K | Hold |
41,169
| – | – | ﹤0.01% | 2400 |
|
|
2013
Q2 | $184K | Buy |
+41,169
| New | +$185K | ﹤0.01% | 2405 |
|
Other funds holding PGNX
Metropolitan Life Insurance Company (MetLife)'s PGNX Position: Q2 2020 in Review
Metropolitan Life Insurance Company (MetLife) sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 30,577 shares — an estimated $116K sold.
Metropolitan Life Insurance Company (MetLife) first reported a position in PGNX in Q2 2013 and held it in 26 quarters. The position peaked at $456K in Q1 2017. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.
- Metropolitan Life Insurance Company (MetLife) reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
- Metropolitan Life Insurance Company (MetLife) sold 30,577 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $116K.
- Metropolitan Life Insurance Company (MetLife) first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 26 quarters.
- Metropolitan Life Insurance Company (MetLife)'s Progenics Pharmaceuticals Inc position peaked at $456K in Q1 2017.
- 3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.
Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2020, filed 14 Aug 2020.